Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics Plc. (ADAPY)
:ADAPY
ADAPY Stock Chart & Stats
$0.06
-$0.04(-6.19%)
At close: 4:00 PM EST
$0.06
-$0.04(-6.19%)
Day’s Range― - ―
52-Week Range$0.02 - $0.74
Previous CloseN/A
VolumeN/A
Average Volume (3M)83.08M
Market Cap
$9.36M
Enterprise ValueN/A
Total Cash (Recent Filing)$26.06M
Total Debt (Recent Filing)$48.68M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding265,051,600
10 Day Avg. Volume5,386,642
30 Day Avg. Volume83,080,105
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)11.47
Price to Sales (P/S)0.76
P/FCF Ratio-1.79
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$27.44M
Bulls Say, Bears Say
Bulls Say
Asset SaleAdaptimmune has agreed to sell key cell therapies to US WorldMeds for up to $85M, including a $55M upfront payment.
Expansion Of Treatment CentersThe company reported 16 invoiced patients in 2Q, and 30 authorized treatment centers now accepting referrals.
Revenue GrowthTecelra net product revenue for 2Q25 was $11.1M, above consensus estimate and grew ~178% from 1Q25.
Bears Say
Preclinical AssetsThe sale of key assets leaves the company with preclinical assets that are still in the early stages of development.
Stock DowngradeAdaptimmune's stock rating has been downgraded to Neutral from Buy due to the absence of significant near-term opportunities.
Workforce ReductionThe company announced plans to reduce its workforce by 62% as well as the departure of several C-suite executives.
Adaptimmune Therapeutics News
ADAPY FAQ
What was Adaptimmune Therapeutics Plc.’s price range in the past 12 months?
Adaptimmune Therapeutics Plc. lowest stock price was $0.02 and its highest was $0.74 in the past 12 months.
What is Adaptimmune Therapeutics Plc.’s market cap?
Adaptimmune Therapeutics Plc.’s market cap is $9.36M.
When is Adaptimmune Therapeutics Plc.’s upcoming earnings report date?
Adaptimmune Therapeutics Plc.’s upcoming earnings report date is Mar 10, 2026 which is in 110 days.
How were Adaptimmune Therapeutics Plc.’s earnings last quarter?
Currently, no data Available
Is Adaptimmune Therapeutics Plc. overvalued?
According to Wall Street analysts Adaptimmune Therapeutics Plc.’s price is currently Overvalued.
Does Adaptimmune Therapeutics Plc. pay dividends?
Adaptimmune Therapeutics Plc. does not currently pay dividends.
What is Adaptimmune Therapeutics Plc.’s EPS estimate?
Adaptimmune Therapeutics Plc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adaptimmune Therapeutics Plc. have?
Adaptimmune Therapeutics Plc. has 265,051,600 shares outstanding.
What happened to Adaptimmune Therapeutics Plc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adaptimmune Therapeutics Plc.?
Currently, no hedge funds are holding shares in ADAPY
Company Description
Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics is a biotechnology company specializing in the development of T-cell therapy for cancer treatment. The company focuses on harnessing the power of the immune system to create innovative therapies that target specific cancer antigens, particularly in the sectors of oncology and immunotherapy. Adaptimmune's core products include its proprietary SPEAR T-cell therapies, which are designed to treat a variety of cancers, including solid tumors and hematologic malignancies.
Technical Analysis
Mersana Therapeutics
―
BioAtla
―
LAVA Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―
Ownership Overview
38.27% Insiders
0.13% Mutual Funds
7.53% Other Institutional Investors
54.07% Public Companies and
Individual Investors